Agency Information Collection Activities: Proposed Collection; Comment Request, 12978-12979 [2017-04499]
Download as PDF
<![CDATA[
12978
Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices
Dated: March 2, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–04500 Filed 3–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSK3G9T082PROD with NOTICES
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Program Project Grant P01.
Date: March 24, 2017.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Video
Conference Meeting).
Contact Person: Ana Olariu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–9223, Ana.Olariu@nih.gov.
Name of Committee: National Institute of
Neurological Disorder and Stroke, Special
Emphasis Panel; R21: Rapid Assessment of
Zika Virus (ZIKV) Complications.
Date: April 5, 2017.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Ana Olariu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–9223, Ana.Olariu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: March 1, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–04485 Filed 3–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Number of
respondents
Purpose of submission
Notification of Intent for Qualifying Other Practitioner to Use Schedule III,
IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment
of Opiate Addiction by a ‘‘Qualifying Other Practitioner’’ under 21 USC
§ 823(g)(2)—Nurse Practitioners ..................................................................
VerDate Sep<11>2014
17:34 Mar 07, 2017
Jkt 241001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Proposed Project: Notification of Intent
To Use Schedule III, IV, or V Opioid
Drugs for the Maintenance and
Detoxification Treatment of Opiate
Addiction by a ‘‘Qualifying Other
Practitioner’’—(OMB No. 0930–0369)—
Extension
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) is requesting an extension
from the Office of Management and
Budget (OMB) for approval of the
Notification of Intent to Use Schedule
III, IV, or V Opioid Drugs for the
Maintenance and Detoxification
Treatment of Opiate Addiction by a
‘‘Qualifying Other Practitioner. The
Notification of Intent would allow
SAMHSA to determine whether other
practitioners are eligible to prescribe
certain approved narcotic treatment
medications for the maintenance or
detoxification treatment of opioid
addiction.
This Notification of Intent is a result
of the Comprehensive Addiction and
Recovery Act (PL 114–198), which was
signed into law on July 22, 2016. The
law establishes criteria for nurse
practitioners (NPs) and physician
assistants (PAs) to qualify for a waiver
to prescribe covered medications. To be
eligible for a waiver, the NP or PA must:
Be licensed under State law to prescribe
schedule III, IV, or V medications for the
treatment of pain; fulfill qualification
requirements in the law for training and
experience; and fulfill qualification
requirements in the law for appropriate
supervision by a qualifying physician.
SAMHSA has the responsibility to
receive, review, approve, or deny waiver
requests.
Practitioners who meet the statutory
requirements will be eligible to
prescribe only those opioid treatment
medications that are controlled in
Schedules III, IV, or V, under the
Controlled Substance Act (CSA), that
are specifically approved by the Food
and Drug Administration (FDA) for the
treatment of opioid addiction, and are
not the subject of an ‘‘adverse
determination.’’ The only medications
that currently fulfill these requirements
are ones that contain the active
ingredient buprenorphine.
The following table is the estimated
hour burden:
Responses/
respondent
816
E:\FR\FM\08MRN1.SGM
Burden hours
1
08MRN1
.066
Total burden
hours
54
12979
Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices
Number of
respondents
Purpose of submission
Responses/
respondent
Burden hours
Total burden
hours
Notification of Intent for Qualifying Other Practitioner to Use Schedule III,
IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment
of Opiate Addiction by a ‘‘Qualifying Other Practitioner’’ under 21 USC
§ 823(g)(2)—Physician Assistants ...............................................................
590
1
.066
39
Total ..........................................................................................................
1,406
........................
........................
93
Send comments to Summer King,
SAMHSA Reports Clearance Officer,
5600 Fishers Lane, Room 15E57–B,
Rockville, Maryland 20857, OR email a
copy to summer.king@samhsa.hhs.gov.
Written comments should be received
by May 8, 2017.
Summer King,
Statistician.
[FR Doc. 2017–04499 Filed 3–7–17; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
mstockstill on DSK3G9T082PROD with NOTICES
Project: Children’s Mental Health
Initiative National Evaluation—NEW
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Mental Health
Services (CMHS) is requesting approval
from the Office of Management and
Budget (OMB) for the new collection of
data for the Children’s Mental Health
Initiative (CMHI) National Evaluation.
Evaluation Plan and Data Collection
Activities. The purpose of the Children’s
Mental Health Initiative (CMHI)
National Evaluation is to assess the
success of the CMHI grants in
expanding and sustaining the reach of
SOC values, principles, and practices.
These include maximizing system-level
coordination and planning, offering a
comprehensive array of services, and
prioritizing family and youth
involvement. In order to obtain a clear
picture of CMHI grant activities, this
longitudinal, multi-level evaluation will
measure activities and performance of
VerDate Sep<11>2014
17:34 Mar 07, 2017
Jkt 241001
grantees essential to building and
sustaining effective Systems of Care
(SOC)’s.
Data collection activities will occur
through four evaluation components.
Each component includes data
collection activities and analyses
involving similar topics. Each
component has one or more instruments
that will be used to address various
aspects. The four components with their
corresponding data collection activities
are as follows:
(1) The Implementation Assessment is
designed using a strategic framework
that provides five analytic dimensions:
(1) Policies, (2) services/supports, (3)
financing, (4) training/workforce, and
(5) strategic communications. These
dimensions cut across the State System,
Local System and Service Delivery
levels and together link to a range of
proximal and distal outcomes. The
evaluation will identify and assess the
mechanisms and strategies employed to
implement and expand systems of care,
and explore the impact on system
performance and child and family
outcomes. Evaluation activities are
framed by the five strategic areas to
examine whether specific mechanisms
and strategies lead to proximal and
distal outcomes. System of care
principles are woven throughout the
framework at both the State and Local
levels. Data collection activities include:
(A) Key Partner Interviews with highlevel administrators, youth and family
representatives, and child agencies to
organize qualitative data collection into
these five areas and to allow within and
across grantee evaluation of the
implementation and impact of activities
in these areas; and (B) the System of
Care Expansion and Sustainability
Survey (SOCESS), a self-report survey
administered to representatives from
grantee organizations, family and youth
organizations, child-serving sectors,
advocacy organizations for diverse
populations, provider organizations,
and financial officers, among others.
The SOCESS is designed to capture selfreport implementation data in the five
analytic dimensions adopted by the
2015 CMHI National Evaluation.
(2) The Network and Geographic
Analysis Component will use Network
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Analysis Surveys to determine the depth
and breadth of the SOC collaboration
across agencies and organization.
Geographic Information Systems (GIS)
will measure the geographic coverage
and spread of the SOC, including
reaching underserved areas and
populations. At the child/youth and
family level, Census block groups
(derived from home addresses) will be
used to depict the geographic spread of
populations served by SOCs.
(3) The Financial Component involves
the review of implementation grantees’
progress in developing financial
sustainability and expansion plans. The
Financial Mapping Interview and
Financing Plan Survey and Interviews
will be conducted with financial
administrators of Medicaid Agencies,
Mental Health Authorities, mental
health provider trade associations, and
family organizations. The Financial Plan
Interview will focus on how the
financial planning process supported or
hindered attainment of sustainable
financing. The Benchmarking Analysis
will compare relative rates of access,
utilization, and costs for children’s
mental health services using the
Benchmarking Tool and administrative
data requested from financial
administrators and personnel working
with Medicaid Agency and Mental
Health Authority reporting and payment
systems.
(4) The Child and Family Outcome
Component will collect longitudinal
data on child clinical and functional
outcomes, family outcomes, and child
and family background. Data will be
collected at intake, 6-months, and 12months post service entry (as long as the
child/youth is still receiving services).
Data will also be collected at discharge
if the child/youth leaves services before
the 12-month data collection point. Data
will be collected using the following
scales for youth age five and older: (A)
a shortened version of the Caregiver
Strain Questionnaire, (B) the Columbia
Impairment Scale, (C) the Pediatric
Symptom Checklist-17, and (D)
background information gathered
through SAMHSA National Outcomes
Measures (NOMS). Data for youth age 0–
4 will be collected using the: (A) Baby
Pediatric Symptom Checklist; (B) Brief
E:\FR\FM\08MRN1.SGM
08MRN1
]]>Agencies
[Federal Register Volume 82, Number 44 (Wednesday, March 8, 2017)]
[Notices]
[Pages 12978-12979]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04499]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995 concerning opportunity for public comment on proposed
collections of information, the Substance Abuse and Mental Health
Services Administration (SAMHSA) will publish periodic summaries of
proposed projects. To request more information on the proposed projects
or to obtain a copy of the information collection plans, call the
SAMHSA Reports Clearance Officer on (240) 276-1243.
Comments are invited on: (a) Whether the proposed collections of
information are necessary for the proper performance of the functions
of the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: Notification of Intent To Use Schedule III, IV, or V
Opioid Drugs for the Maintenance and Detoxification Treatment of Opiate
Addiction by a ``Qualifying Other Practitioner''--(OMB No. 0930-0369)--
Extension
The Substance Abuse and Mental Health Services Administration
(SAMHSA) is requesting an extension from the Office of Management and
Budget (OMB) for approval of the Notification of Intent to Use Schedule
III, IV, or V Opioid Drugs for the Maintenance and Detoxification
Treatment of Opiate Addiction by a ``Qualifying Other Practitioner. The
Notification of Intent would allow SAMHSA to determine whether other
practitioners are eligible to prescribe certain approved narcotic
treatment medications for the maintenance or detoxification treatment
of opioid addiction.
This Notification of Intent is a result of the Comprehensive
Addiction and Recovery Act (PL 114-198), which was signed into law on
July 22, 2016. The law establishes criteria for nurse practitioners
(NPs) and physician assistants (PAs) to qualify for a waiver to
prescribe covered medications. To be eligible for a waiver, the NP or
PA must: Be licensed under State law to prescribe schedule III, IV, or
V medications for the treatment of pain; fulfill qualification
requirements in the law for training and experience; and fulfill
qualification requirements in the law for appropriate supervision by a
qualifying physician. SAMHSA has the responsibility to receive, review,
approve, or deny waiver requests.
Practitioners who meet the statutory requirements will be eligible
to prescribe only those opioid treatment medications that are
controlled in Schedules III, IV, or V, under the Controlled Substance
Act (CSA), that are specifically approved by the Food and Drug
Administration (FDA) for the treatment of opioid addiction, and are not
the subject of an ``adverse determination.'' The only medications that
currently fulfill these requirements are ones that contain the active
ingredient buprenorphine.
The following table is the estimated hour burden:
----------------------------------------------------------------------------------------------------------------
Number of Responses/ Total burden
Purpose of submission respondents respondent Burden hours hours
----------------------------------------------------------------------------------------------------------------
Notification of Intent for Qualifying Other 816 1 .066 54
Practitioner to Use Schedule III, IV, or V
Opioid Drugs for the Maintenance and
Detoxification Treatment of Opiate Addiction by
a ``Qualifying Other Practitioner'' under 21
USC Sec. 823(g)(2)--Nurse Practitioners......
[[Page 12979]]
Notification of Intent for Qualifying Other 590 1 .066 39
Practitioner to Use Schedule III, IV, or V
Opioid Drugs for the Maintenance and
Detoxification Treatment of Opiate Addiction by
a ``Qualifying Other Practitioner'' under 21
USC Sec. 823(g)(2)--Physician Assistants.....
---------------------------------------------------------------
Total....................................... 1,406 .............. .............. 93
----------------------------------------------------------------------------------------------------------------
Send comments to Summer King, SAMHSA Reports Clearance Officer,
5600 Fishers Lane, Room 15E57-B, Rockville, Maryland 20857, OR email a
copy to summer.king@samhsa.hhs.gov. Written comments should be received
by May 8, 2017.
Summer King,
Statistician.
[FR Doc. 2017-04499 Filed 3-7-17; 8:45 am]
BILLING CODE 4162-20-P
